Jubilant Pharmova target cut 16%: key risks in 2026

What changed for Jubilant Pharmova

Two brokerages, Nuvama Institutional Equities and Nirmal Bang Institutional Equities, trimmed their target prices for Jubilant Pharmova while retaining a ‘buy’ rating on the stock. Nuvama cut its target price by 16% to INR 1,300, while Nirmal Bang cut its target by 13% to INR 1,175. The revisions came alongside near-term operational concerns linked to the company’s Montreal facility in Canada, and product supply issues in a key imaging segment.

The stock reaction was negative in the session referenced in the update. At 0956 IST, Jubilant Pharmova shares were down over 3% at INR 905.75 on the National Stock Exchange. Separate price snapshots in the provided material also show moves such as 1,006.35 (-0.52%) and 997.00 (-1.41%) “as on 22 May, 2026 | 03:56”, indicating the day included multiple volatile prints.

Broker calls: targets cut, buy rating retained

The broker actions were specific on the magnitude of the cuts and the revised targets. Nuvama and Nirmal Bang lowered their targets to INR 1,300 and INR 1,175, respectively, even as both retained their ‘buy’ stance. This combination typically signals that analysts still see longer-term value, but believe near-term execution risks or earnings estimates need recalibration.

Alongside the target revisions, the broader set of brokerage notes included other target levels for Jubilant Pharmova. The material references a report where Shrikant Akolkar of Nuvama maintained a ‘Buy’ rating with a price target of INR 1,385, and another note that initiated coverage at a ‘BUY’ with an SotP-derived target price of INR 1,450, citing an upside potential of about 30% from a referenced closing price. Since these targets appear in different contexts, they should be read as separate research notes rather than a single unified street view.

Montreal facility: remediation and shutdown risk

Nuvama flagged that near-term performance could be impacted by remediation or a shutdown of Jubilant Pharmova’s facility at Montreal in Canada. The note also linked the risk to regulatory observations described as “official action indicated” (OAI) observations. Remediation-related disruptions can affect shipment schedules, utilisation rates, and customer confidence for contract manufacturing operations.

The material provides a concrete cost datapoint tied to this issue. During the December quarter, the company incurred a cost of INR 443 million pursuant to the temporary suspension of manufacturing operations for remediation of OAI observations at its Montreal contract manufacturing facility. While the update does not quantify the duration of the suspension, it clearly connects a financial hit to the remediation action.

Supply shortages in SPECT products

Another factor cited by Nuvama was supply shortages of single-photon emission computed tomography (SPECT) products. SPECT is used in nuclear medicine imaging, and supply constraints in radiopharmaceutical or imaging-related lines can affect revenue timing and customer fulfilment.

The update does not specify which products were impacted or how long the shortage is expected to persist. But it frames shortages as a near-term headwind, alongside Montreal remediation and higher depreciation. Together, these items point to a period where earnings could be pressured by operational and accounting cost factors.

Higher depreciation adds to near-term pressure

Nuvama also highlighted higher depreciation as a reason for near-term impact. Depreciation can rise when new capacities come on stream, when capitalised remediation-related investments are made, or when asset base expands. The note does not provide the size of the depreciation change, but it is explicitly listed as part of the expected near-term drag.

For investors, depreciation is important because it can lower reported profit even when cash flows are less affected. In valuation work that relies on P/E or PAT-based metrics, higher depreciation can compress earnings multiples and prompt target-price adjustments.

Price action and volatility: what the data shows

The supplied material contains multiple price references across dates and times, reflecting varied market conditions and commentary. One snapshot shows the stock down over 3% at INR 905.75 at 0956 IST. Another note says the share price declined 4.66% to the lowest level since Oct. 4 before paring losses to trade 3.77% lower at Rs 1,070.05 as of 12:20 p.m., compared with a 0.45% decline in the NSE Nifty 50.

It also lists broader trading parameters such as 52-week levels and bands. The 52-week high is shown as INR 1,309.90 (07-Nov-2024) and the 52-week low as INR 802.00 (07-Apr-2025). The price band is indicated at 20%, with an upper band of INR 1,372.40 and a lower band of INR 915.00. A daily volatility of 2.48 and annualised volatility of 47.38 are also mentioned in the dataset.

Key facts table

Analyst consensus snapshot cited

The material also includes an “Analysts’ Consensus” block. It shows a mean consensus of BUY, number of analysts at 2, last close price of INR 1,222.80, and an average target price of INR 1,299.50. It also lists a high price target of INR 1,385.00 and a low price target of INR 1,214.00.

Separately, another part of the material suggests “The word on The Street” indicates a Hold consensus rating, which conflicts with the BUY consensus block. Since both statements appear in the provided text, readers should treat this as a reflection of mixed sourcing rather than a definitive consensus number.

Why this matters for investors

The core issue is that the Montreal facility remediation and potential shutdown risk has moved from a background concern to a factor explicitly shaping broker target prices. The INR 443 million cost booked in the December quarter ties the issue to realised financial impact, not only forward risk. Alongside this, SPECT supply shortages and higher depreciation point to a cluster of near-term pressure points.

At the same time, the continued ‘buy’ ratings from the two brokerages that cut targets indicate they still see value beyond the near-term disruption. For market participants, the next key monitoring points remain operational stability at Montreal, any clarity on supply normalisation for SPECT products, and the trajectory of depreciation and earnings delivery in subsequent quarters.

Conclusion

Nuvama and Nirmal Bang cut Jubilant Pharmova’s target prices to INR 1,300 and INR 1,175, but retained ‘buy’ ratings, citing Montreal remediation risk, SPECT supply shortages, and higher depreciation. The stock was down over 3% at INR 905.75 at 0956 IST in the referenced session, and the material highlights a December-quarter cost of INR 443 million linked to the Montreal suspension. Investors are likely to track further disclosures around remediation progress and supply recovery, as these were the specific factors driving the target revisions.